Adiposity shapes the immune architecture independent of antibody responses in mild SARS-CoV-2 Infection.

Publication date: Jun 26, 2026

Adiposity is linked to immune dysregulation, yet the extent to which body composition shapes the immune architecture and antibody responses after mild SARS-CoV-2 infection remains unclear. We examined how body composition relates to immune organization in a large, low-comorbidity cohort. In a subgroup of the DORM trial, segmental bioelectrical impedance was used to derive fat- and muscle-dominant components. Immune phenotypes were quantified by multiparametric flow cytometry, and neutralizing activity by a spike ACE2-RBD surrogate neutralization assay. Associations were tested using multivariable generalized linear models with effect modification by infection status; immune organizational endotypes were identified by k-means clustering. We included 1,005 predominantly healthy men (mean age 32. 5 years; 591 seropositive and 414 seronegative), largely from India and Bangladesh. Fat mass, but not muscle mass, was the principal determinant of immune variation. Higher fat mass was associated with increased nacEFve B cells, elevated class-switch ratios, higher CD4 T-cell proportions, and reduced CD8 T-cell frequencies. These associations were independent of major metabolic covariates and were modified by infection status for T-cell subsets. In contrast, fat mass showed only weak and non-significant associations with neutralizing antibody activity. Clustering analyses identified adiposity-aligned immune endotypes characterized by coordinated shifts in B- and T-cell composition but minimal differences in neutralizing responses. Adiposity is associated with distinct alterations in immune architecture, particularly affecting B-cell and T-cell composition, even in the absence of overt impairment in antibody neutralization.

Open Access PDF

Concepts Keywords
Antibody adiposity
Cd4 B-cell maturation
Dysregulation body composition
Models neutralizing antibodies
SARS-CoV-2

Semantics

Type Source Name
disease MESH SARS-CoV-2 Infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
disease MESH included
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
drug DRUGBANK Isoxaflutole
drug DRUGBANK Angiotensin II
drug DRUGBANK BIA
drug DRUGBANK Pidolic Acid
disease MESH PCA
disease MESH inflammation
disease MESH obesity
disease MESH asymptomatic infection
disease MESH severe obesity
disease MESH CD24^hiCD38^hi
disease MESH strain
drug DRUGBANK Human Serum Albumin
drug DRUGBANK Phosphate ion

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *